Sight Sciences (SGHT) said late Tuesday that a 36-month study evaluating the long-term effectiveness of its OMNI Surgical System in treating primary open-angle glaucoma demonstrated sustained reductions in intraocular pressure and medication use.
Mean intraocular pressure reductions ranged from 5.6 mmHg to 7.1 mmHg with greater declines in patients with higher baseline, the company said.
The results show significant decreases in utilization of medications through 18 months postoperatively, the company added.
The study evaluated 230 eyes of 196 patients with primary open-angle glaucoma.
Shares of the company were up 1.5% in recent after-hours activity.
Price: 3.36, Change: +0.05, Percent Change: +1.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.